Ken Rehder, PhD, has more than 30 years of experience in synthetic organic chemistry, medicinal chemistry, and preclinical drug development. Dr Rehder is currently the director of Innovation and Intellectual Property Development for Discovery – Science - Technology. He is also principal investigator of the National Institute for Mental Health Chemical Synthesis and Drug Supply Program.
Dr. Rehder has served as project manager for two National Institute on Drug Abuse-funded translational medicine cooperative agreements, both of which resulted in RTI proprietary compounds reaching Phase 1 clinical trials. He has managed multiple collaborative drug discovery, medicinal chemistry, lead optimization, and preclinical-to-clinical projects, and has had managerial responsibility for multiple scientific departments.
Dr. Rehder's current interests include coordinating multidisciplinary, multiorganizational projects of significant scientific, logistical, and managerial complexity, particularly those involving intellectual property.
